Assembly biosciences to highlight data from hbv core inhibitor programs at easl's international liver congress™ 2022

South san francisco, calif., june 08, 2022 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis b virus (hbv) and other viral diseases, today announced that six abstracts have been accepted for presentation at the international liver congress™, the annual meeting of the european association for the study of the liver (easl) taking place virtually and in london on june 22-26, 2022. during the meeting, data from assembly bio's investigational core inhibitor programs, vebicorvir (vbr), abi-h3733 (3733) and abi-4334 (4334), will be featured in six poster presentations.
ASMB Ratings Summary
ASMB Quant Ranking